Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04907942 · ClinicalTrials.gov registry record · NA
Ecological Momentary Assessment and Text Message Intervention for Stress Management
A NA study, sponsored by Click Therapeutics.
- Completed
- Registry status
- NA
- Development phase
- 81
- Enrollment target
NCT04907942: Completed NA study, sponsored by Click Therapeutics.
NCT04907942 is a NA study that has completed, run by Click Therapeutics. The registered enrollment target is 81 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (94% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04907942, a NA study, has completed, sponsored by Click Therapeutics.
- COMPLETED
- Registry status
- NA
- Development phase
- 81 participants
- Enrollment target
Study Summary
Feasibility and acceptability of an Ecological Momentary Assessment (EMA) compared with an EMA plus automated text message intervention for stress management
Primary Outcome
The main outcome of the FACE STRESS study is to evaluate feasibility of an EMA and EMA plus text message intervention (EMA+), assessed by the number of completed individuals after the initial screening, from zero as worst to all subjects (best)
Interventions
- OTHER EMA + EMA and FACE Stress
- OTHER EMA Alone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 81 participants |
| Start Date | 2020-10-29 |
| Est. Completion | 2021-06-20 |
| Phase | NA |
What the finished NCT04907942 record still lists
NCT04907942 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 81 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (94% lower).
The record links to 0 conditions, and to 2 interventions - of which EMA + EMA and FACE Stress is the first listed.
NCT04907942 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04907942 about?
NCT04907942 is a clinical study titled "Ecological Momentary Assessment and Text Message Intervention for Stress Management". Feasibility and acceptability of an Ecological Momentary Assessment (EMA) compared with an EMA plus automated text message intervention for stress management
What is the current status of trial NCT04907942?
This trial is currently completed. It is a NA study. The enrollment target is 81 participants. The study started on 2020-10-29. Estimated completion is 2021-06-20.
What interventions are being tested in trial NCT04907942?
The interventions under investigation include: EMA + EMA and FACE Stress (OTHER), EMA Alone (OTHER).
Who is sponsoring clinical trial NCT04907942?
This trial is sponsored by Click Therapeutics, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04907942's enrollment target sits among peer trials
81 992nd of 2000 higher than 1,007 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04966481 · 81 participants · Phase 3
Palbociclib and Cetuximab Versus Cetuximab Monotherapy for Patients With CDKN2A-altered, HPV-unrelated Head and Neck Squamous Cell Carcinoma Who Experienced Disease Progression on a PD-1/L1 Inhibitor
- NCT05109429 · 81 participants · NA
Developing a Clinical Outcome Assessment for Opioid Craving
- NCT05112601 · 81 participants · Phase 2
Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma
- NCT05305911 · 81 participants · Phase 2
Sodium Glucose Co-Transporter 2 (SGLT2) and STEMI
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI